First study of neoadjuvant use of PARP inhibitor shows promise for early-stage, BRCA+ breast cancer patients
In a small Phase II study of early-stage breast cancer patients with BRCA1/2 mutations, researchers at The University of Texas MD Anderson Cancer Center found that more than half of the women who took the PARP inhibitor talazoparib once daily prior to surgery had no evidence of disease at the time of surgery. If further validated in larger, confirmatory trials, the oral medication could replace chemotherapy for these patients.
...
Erdafitinib shows promise in urothelial cancer patients with specific mutations
In an international Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center, treatment with the oral FGFR...
Study of acute myeloid leukemia patients shows protein inhibitor drug safe and effective with durable remissions
Ivosidenib, an experimental drug that inhibits a protein often mutated in several cancers has been shown to be safe, resulting in durable...
Long-term IMPACT data find improved survival when targeted therapies matched to tumor-specific gene mutations
Matching targeted therapies to tumor-specific gene mutations across tumor types improved progression-free survival (PFS) and overall survival (OS) in patients with advanced disease relative to those receiving non-matched treatment (NMT), according to research from The University of Texas MD Anderson Cancer Center. The researchers also found that receiving matched targeted therapy (MTT) was an independent factor for predicting longer OS...
MD Anderson Informs Patients of Accidental Disclosure of Email Addresses
The University of Texas MD Anderson Cancer Center today sent letters to individuals whose email addresses were accidentally exposed in a communication...
MD Anderson and Amgen to accelerate early-stage treatments for several cancer types
The University of Texas MD Anderson Cancer Center and Amgen today announced two multi-year collaboration agreements aimed at accelerating...
ASCO honors MD Anderson faculty with awards
The American Society of Clinical Oncology (ASCO) will present awards to leaders of cancer care during its annual meeting June 1-5 in Chicago...
MD Anderson and Ipsen announce joint bench-to-bedside cancer drug development partnership
The University of Texas MD Anderson and Ipsen, a global biopharmaceutical group, today announced a global licensing and joint development...
Nursing Leaders from MD Anderson Cancer Center, Seattle Cancer Care Alliance Share Insights on Succession Planning
While some regions of the nation will experience greater nursing shortages than others in the coming years, hospitals and healthcare systems...
Surveillance intensity not associated with earlier detection of recurrence or improved survival in colorectal cancer patients
A national retrospective study led by researchers at The University of Texas MD Anderson Cancer Center found no association between intensity...
Self-reporting with sensor and mobile technology may reduce symptom burden for head and neck cancer patients undergoing radiation treatment
Abstract: 6063
A study led by researchers at The University of Texas MD Anderson Cancer Center found that the use of at-home sensor...
New approach to cancer research aims to accelerate studies and reduce cost
A new model for improving how clinical trials are developed and conducted by bringing together academic cancer experts and pharmaceutical...
Preclinical MD Anderson study suggests ARID1a may be useful biomarker for immunotherapy
Functional loss of ARID1a, a frequently mutated tumor suppressor gene, causes deficiencies in normal DNA repair and may sensitize tumors to...
MD Anderson, Spectrum Pharmaceuticals complete poziotinib licensing deal
The University of Texas MD Anderson Cancer Center and Spectrum Pharmaceuticals have signed a licensing agreement that covers discoveries by...